Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients
Mirco Friedrich, Paola Neri, Niklas Kehl, et al.
Cancer Cell (2023) Vol. 41, Iss. 4, pp. 711-725.e6
Open Access | Times Cited: 123

Showing 1-25 of 123 citing articles:

T cells in health and disease
Lina Sun, Yanhong Su, Anjun Jiao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 355
Multiple myeloma
Florent Malard, Paola Neri, Nizar J. Bahlis, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 46
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms
Holly Lee, Paola Neri, Nizar J. Bahlis
Blood (2024) Vol. 143, Iss. 13, pp. 1211-1217
Open Access | Times Cited: 25
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy
Michael Hallek
American Journal of Hematology (2025)
Open Access | Times Cited: 3
Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy
Johannes Duell, Alexander Leipold, Silke Appenzeller, et al.
Blood (2023) Vol. 143, Iss. 8, pp. 685-696
Closed Access | Times Cited: 24
Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
Monika Engelhardt, K. Martin Kortüm, Hartmut Goldschmidt, et al.
Haematologica (2024)
Open Access | Times Cited: 14
T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple Myeloma
Christie P.M. Verkleij, Chloe O’Neill, Marloes E.C. Broekmans, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 14, pp. 3006-3022
Closed Access | Times Cited: 14
High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
Matthew Rees, Shaji Kumar
American Journal of Hematology (2024) Vol. 99, Iss. 8, pp. 1560-1575
Closed Access | Times Cited: 12
Bispecific antibodies in the treatment of multiple myeloma
Anup J. Devasia, Ajai Chari, Guido Lancman
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Bispecific antibodies: advancing precision oncology
M. Zurita Herrera, G. Pretelli, Jayesh Desai, et al.
Trends in cancer (2024) Vol. 10, Iss. 10, pp. 893-919
Open Access | Times Cited: 11
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
Ross Firestone, Nicholas D. Socci, Tala Shekarkhand, et al.
Blood (2024) Vol. 144, Iss. 4, pp. 402-407
Open Access | Times Cited: 10
CD4+ CAR-T cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR-T cell therapy
Guy Ledergor, Zenghua Fan, Kaichun Wu, et al.
Blood Advances (2024) Vol. 8, Iss. 13, pp. 3562-3575
Open Access | Times Cited: 9
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
Diana Cortés‐Selva, Tatiana Perova, Sheri Skerget, et al.
Blood (2024) Vol. 144, Iss. 6, pp. 615-628
Open Access | Times Cited: 9
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
Matthew Rees, Mattia D’Agostino, Lisa Leypoldt, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 9
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
Johannes M. Waldschmidt, Noori Sotudeh, Sankalp Arora, et al.
Blood Advances (2025)
Open Access | Times Cited: 1
Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma
Clara Kolbe, Joseph Kauer, Berit J. Brinkmann, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 1, pp. e009245-e009245
Open Access | Times Cited: 1
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Raphael Lutz, Alexandra M. Poos, Llorenç Solé‐Boldo, et al.
Science Immunology (2025) Vol. 10, Iss. 104
Open Access | Times Cited: 1
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Ross Firestone, Devin McAvoy, Tala Shekarkhand, et al.
Blood Advances (2023) Vol. 8, Iss. 7, pp. 1600-1611
Open Access | Times Cited: 20
T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
Niels W.C.J. van de Donk, Chloe O’Neill, Maaike E. M. de Ruijter, et al.
Current Opinion in Oncology (2023) Vol. 35, Iss. 6, pp. 601-611
Open Access | Times Cited: 19
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
Francesco Maura, Eileen M. Boyle, David G. Coffey, et al.
Nature Cancer (2023) Vol. 4, Iss. 12, pp. 1660-1674
Closed Access | Times Cited: 18
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Aina Oliver‐Caldés, Marta Español‐Rego, Aintzane Zabaleta, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 10, pp. 2085-2096
Closed Access | Times Cited: 7
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins
Paola Neri, Noémie Leblay, Holly Lee, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 8, pp. 590-609
Closed Access | Times Cited: 7
Mechanisms of resistance to bispecific T cell engagers in multiple myeloma and their clinical implications
Éric Letouzé, Philippe Moreau, Nikhil Munshi, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2952-2959
Open Access | Times Cited: 6
Immune status and selection of patients for immunotherapy in myeloma: a Proposal
Madhav V. Dhodapkar
Blood Advances (2024) Vol. 8, Iss. 10, pp. 2424-2432
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top